 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Apr 29, 2024 |
| Title |
PRMT1 Promotes Epigenetic Reprogramming Associated with Acquired Chemoresistance in Pancreatic Cancer |
| Organism |
Mus musculus |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
Pancreatic Ductal Adenocarcinoma (PDAC) is associated with extremely poor prognosis due to late diagnosis and therapeutic resistance. Here we show that PDAC cells undergo progressive reprogramming of the global epigenetic landscape during the process of acquiring chemoresistance. Through an epigenetic inhibitor screen, we identified Protein Arginine methyltransferase 1 (PRMT1) as a central driver of chemoresistance in PDAC. Genetic or pharmacological inhibition of PRMT1 impaired adaptive epigenetic reprogramming, sensitized PDAC cells to Gemcitabine and other commonly used chemo drugs, and delayed the development of acquired resistance both in vitro and in vivo. Mechanistically, we find that PRMT1, through its enzymatic activity, limits the accumulation of small bZIP transcription factor MAFF in the nucleus, and the assembly of chromatin-bound MAFF/BACH1 hetero-oligomeric complexes following Gemcitabine treatment. Genetic silencing of MAFF heightened the resistance of PDAC cells to Gemcitabine, and to combination of Gemcitabine and PRMT1 inhibitors. Cut&Tag chromatin profiling of H3K27Ac, MAFF and BACH1 suggests a pivotal role for MAFF/BACH1 in orchestrating global epigenetic reprogramming during the course of acquiring Gemcitabine resistance. Supporting the clinical relevance of our findings, predicted PRMT1 and MAFF/BACH1 genes signatures based on our Cut&Tag analysis were able to distinguish Gemcitabine-resistant from Gemcitabine-sensitive PDAC patient-derived xenografts according to expression changes induced by Gemcitabine. Together, our study reveals a novel epigenetic regulatory axis involving PRMT1 and MAFF/BACH1 that modulates Gemcitabine response, which could be potentially exploited for improving therapeutic response in advanced PDAC.
|
| |
|
| Overall design |
Cut&Tag Chromatin Profiling of H3K27Ac, MAFF, and BACH1 for Pancreatic Ductal Adenocarcinoma (PDAC). (1) Time series analysis of PDAC under GEM treatment at D0,2,4,6,8,10. (2) KD
|
| |
|
| Contributor(s) |
Nguyen C, Murakami S, McIntosh A, Nas R, Colon-Emeric B, Yi C |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Mar 10, 2023 |
| Last update date |
Apr 30, 2024 |
| Contact name |
Chan Dinh Khac Nguyen |
| E-mail(s) |
cdn14@georgetown.edu
|
| Phone |
2028204474
|
| Organization name |
Lombardi Comprehensive Cancer Center
|
| Department |
Oncology
|
| Lab |
E301
|
| Street address |
3970 Reservoir Rd
|
| City |
Washington |
| State/province |
DC |
| ZIP/Postal code |
20057 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (29)
|
|
| Relations |
| BioProject |
PRJNA943270 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE227129_RAW.tar |
1.5 Gb |
(http)(custom) |
TAR (of BW) |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...